Oligonucleotide CDMO Market

The report "Oligonucleotide CDMO Market by Service (Contract Manufacturing (Clinical, Commercial), Development), Type (ASO, SiRNA, (CPG Oligos, gRNA)), Application (Therapeutic, Research, Diagnostic), End User (Pharma, Biotech) - Global Forecast to 2029 ", is projected to reach USD 6.73 billion in 2029 from USD 2.51 billion in 2024, with a CAGR of 21.8%. Factors such as the growing focus on the development and commercialization of oligo-based therapeutics, increasing outsourcing of development and manufacturing to CDMOs, and an increasing focus on a personalized approach to medicine. However, factors such as the high volume of organic & aqueous waste generation and regulatory mandates are posing a challenge to the market growth. Emerging economies are increasingly offering growth opportunities for oligo-CDMO market players.

Browse 270 market data Tables and 56 Figures spread through 254 Pages and in-depth TOC on "Oligonucleotide CDMO Market by Service (Contract Manufacturing (Clinical, Commercial), Development), Type (ASO, SiRNA, (CPG Oligos, gRNA)), Application (Therapeutic, Research, Diagnostic), End User (Pharma, Biotech) - Global Forecast to 2029 "
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/oligonucleotide-cdmo-market-227700087.html

The therapeutic application subsegment accounted for the largest share of the oligonucleotide CDMO  market’s application segment in 2023

Based on applications, the oligonucleotide CDMO market is segmented into therapeutic, diagnostic, and research applications. The therapeutic application segment accounted for the largest share of the oligonucleotide CDMO market by application in 2023. Oligonucleotide-based therapies are being developed for a broad spectrum of indications. Moreover, oligonucleotide therapies are one of the key drug classes for precision medicine, targeting specific genetic mutations in individual patients. The increasing adoption of personalized treatments is further enhancing the demand for therapeutic oligonucleotide manufacturing.

The commercial segment accounted for the largest share of the contract manufacturing market, by stage, during the forecast period.

Based on stage, the oligonucleotide contract manufacturing market is divided into clinical scale and commercial scale. The large share of the commercial segment can be attributed to the fact that commercial manufacturing is an ongoing process throughout the lifecycle of a drug, often spanning years or decades. Thus,  commercial-scale production involves sustained and repeated manufacturing, driving higher revenue. With a growing number of oligonucleotide-based therapies receiving regulatory approvals, the need for large-scale production to meet market demand has surged. Recent approvals in fields like oncology, neurology, and infectious diseases have expanded the market for commercial manufacturing services. CDMOs offer capabilities such as advanced facilities, regulatory expertise, and the capacity to handle large-scale production.

Asia Pacific was registered as the fastest-growing region of the Oligonucleotide CDMO market in 2023.

The oligonucleotide CDMO market is divided into six regions: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America held the largest share of the oligonucleotide CDMO market, followed by Europe. The presence of key market players in the region is a key driving factor. Asia Pacific region is expected to be the fastest growing region during the forecast period owing to factors such as increasing investments by key global players in the region, domestic players enhancing their life sciences infrastructure, and government policies incentivizing R&D are supporting the market growth in the region.

Key players in the oligonucleotide CDMO market include Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Agilent Technologies, Inc. (US), Kaneka Eurogentec S.A. (Belgium), Ajinomoto Co., Inc. (Japan), Aurigene Pharmaceutical Services Ltd. (India), Bachem (Switzerland),  Syngene International Limited (India), PolyPeptide Group (Switzerland), WuXi AppTec (China), EUROAPI (France),  Eurofins Scientific (Luxembourg), GenScript (US), and Danaher Corporation (US), among others.

Don’t miss out on business opportunities in Oligonucleotide CDMO Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]